Delivery Order SPE2DR25D2005-SPE2DR26FE6E1
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 10, 2025, for the supply of Zepbound 7.5 mg/0.5 ml pen injections with a ceiling value of $5,141.16. This is a firm fixed-price delivery order with no set-aside designation, issued under a competitive procurement process. The order is set for completion by September 11, 2025, and will be fulfilled from the vendor's Conshohocken, Pennsylvania facility. This delivery order is a child contract issued...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 14, 2025, for the supply of Zepbound 2.5 mg/0.5 mL pen injections (0.5 mL units) with a ceiling value of $1,659.37. This firm fixed-price delivery order, which is set to be completed by August 15, 2025, will be fulfilled from AmerisourceBergen's Conshohocken, Pennsylvania facility. The award represents a non-competitive delivery order issued under AmerisourceBergen's existing indefinite delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a contract ceiling value of $15,472.34. This is a firm fixed-price delivery order with an ultimate completion date of July 29, 2025, and represents a non-competitive set-aside award. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a $42,081.30 firm fixed-price delivery order to AmerisourceBergen Drug Corp on September 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections with a completion date of September 16, 2025. This is a non-set-aside competitive award issued as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The work will be...
- The Defense Logistics Agency awarded a delivery order valued at $3,188.64 to AmerisourceBergen Drug Corp for Zepbound 7.5 mg/0.5 ml pen injections on July 22, 2025, with an ultimate completion date of July 23, 2025. This is a firm fixed price, non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a comprehensive global pharmaceutical support vehicle valued at $999,999,999.00 and extending through...
- The Defense Logistics Agency awarded a delivery order valued at $6,750.31 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 mL pen injections on August 4, 2025, with an ultimate completion date of August 5, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order is issued under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a $1,525.20 firm fixed price delivery order to AmerisourceBergen Drug Corp on June 3, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. This non-competitive delivery order, with an ultimate completion date of June 4, 2025, represents a small-value transaction executed from AmerisourceBergen's existing indefinite delivery contract with DLA Troop Support Medical. The place of performance is listed as Conshohocken, Pennsylvania, where...
- The Defense Logistics Agency awarded a delivery order valued at $4,575.56 to AmerisourceBergen Drug Corp for the supply of Zepbound 7.5 mg/0.5 ml pen injections on July 24, 2025, with an ultimate completion date of July 25, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and designates Conshohocken, Pennsylvania as the place of performance. The delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $15,251.60 on August 15, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections. The contract, designated as a firm fixed price delivery order with an ultimate completion date of August 18, 2025, represents a non-competitive set-aside award. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location. This delivery order is issued under the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on May 8, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a ceiling value of $2,830. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of May 9, 2025. The product will be delivered to AmerisourceBergen's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- SPE2DR25D2005Indefinite Delivery Contract
- SPE2DR25D2005-SPE2DR26FE6E1Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 4, 2025, for the supply of Zepbound 7.5 mg/0.5 mL pen injections, with a ceiling value of $7,187.24 and ultimate completion date of November 5, 2025. This is a firm fixed-price, competitively awarded contract with no set-aside designation. The order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.99 billion comprehensive pharmaceutical support vehicle running through December 2026 that enables the company to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor for military and veteran healthcare systems. As a prime contractor under the DLA's Medical Supply Chain, the company fulfills delivery orders for various therapeutic pharmaceuticals ranging from diabetes medications to specialty treatments across multiple medical domains. The delivery order for Zepbound, a GLP-1 receptor agonist used in diabetes and weight management treatment, reflects the company's role in providing essential medications to support Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.2k | 11/4/25 |